Overview

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

Status:
Terminated
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
This trial is aimed at studying the antiviral activity, toxicity and pharmacokinetic (PK) interactions of tenofovir DF and atazanavir enhanced with low dose of ritonavir given alone and then concomitantly as part of a salvage regimen to HIV patients with multiple failure, under conditions allowing to tease out the specific role of atazanavir combined with low dose of ritonavir.
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators:
Bristol-Myers Squibb
Gilead Sciences
Treatments:
Atazanavir Sulfate
Ritonavir
Tenofovir